Home Health Care Stock Update: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

Stock Update: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

1
0
SHARE

Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) ended Friday session in green amid volatile trading. The shares closed up +0.14 points or 3.44% at $4.21 with 17,075 shares getting traded. Post opening the session at $4.06, the shares hit an intraday low of $4.06 and an intraday high of $4.21 and the price vacillated in this range throughout the day.

Market Cap/Outstanding Shares

The company has a market cap of $90.70 million and the number of outstanding shares have been calculated to be 20.88 million shares.

Performance weekly/monthly/quarterly/yearly in percentage (%)

The performance for the week is valued at 2.43%, resulting in a performance for the month at 10.21%. Therefore, the stated figure displays a quarterly performance of 357.61% and an annual performance of 350.80% traded up 3.44% on 25 November, 2016 hitting $4.21.

EPS (Earning Per Share )

The EPS of SNSS is strolling at -2.94, measuring its EPS growth this year at 29.80%. As a result, the company has an EPS growth of 12.50% for the approaching year. Company’s EPS for the past five years is valued at 12.70%.

Beta/ATR/Volatility

Beta factor is stands at 1.91 and Avg. true range is 0.18. Historically, the volatility of this stock is about 3.90% a week and 4.84% a month.

Sunesis Pharmaceuticals, Inc. (SNSS) recently stated financial results for the third quarter ended September 30, 2016.

Cash, cash equivalents and marketable securities totaled $24.3 million as of September 30, 2016, as contrast to $46.4 million as of December 31, 2015. The decrease of $22.1 million was mainly because of $28.9 million of net cash used in operating activities, $8.0 million of payments against notes payable, partially offset by $14.8 million in net loan proceeds. An additional $25.9 million in net proceeds was raised in the October 2016 equity financing, resulting in pro-forma September 30, 2016 cash, cash equivalents and marketable securities of $50.2 million.  This capital is expected to be sufficient to fund operations into 2018.

Revenue for the three and nine months ended September 30, 2016 was $0.6 million and $1.9 million as contrast to $0.7 million and $2.4 million for the same periods in 2015. The decrease between the periods was mainly because of the extension of the amortization period of our deferred revenue.

Research and development expense was $5.3 million and $18.1 million for the three and nine months ended September 30, 2016 as contrast to $5.3 million and $16.1 million for the same periods in 2015. The increase of $2.0 million between the comparable nine month periods was mainly because of a boost in professional services, clinical trials and medical affairs expenses.

General and administrative expense was $3.9 million and $12.2 million for the three and nine months ended September 30, 2016 as contrast to $4.0 million and $14.3 million for the same periods in 2015.  The decrease of $0.1 million between the comparable three month periods was mainly because of a decrease in personnel expenses. The decrease of $2.1 million between the comparable nine month periods was mainly because of decrease in outside service costs.